Edoc Acquisition Corp. (ADOC) Adds $75M to Calidi Biotherapeutics Deal
by Nicholas Alan Clayton on 2022-03-17 at 7:08am

Edoc (NASDAQ:ADOC) has added a $75 million common stock purchase agreement to its combination with biotech firm Calidi.

As a part of the agreement, Calidi will be able to call upon an unnamed investor to purchase up to $75 million in company stock over a three-year period following close. These shares are to be bought at a 4% discount to the lowest daily VWAP for the three days preceding the purchase.

These purchases will be made for a maximum value of $10 million at a time and or, if lower, in shares equivalent to 30% of the average daily trading volume of Calidi stock in the five preceding days. In exchange for joining the agreement, the investor will also be granted 150,000 shares at close.

Edoc also announced in the 8-K a slight change in terms to the deal’s existing $25 million PIPE, providing a mechanism for damages to PIPE investors should there be delays or failures to notify investors of the registration of their shares.

The SPAC has not yet set a date to vote on the combination, but announced last month that it would transfer 564,847 promote shares (25.1%) to certain investors as a part of a backstop agreement. This agreement also stipulates that Edoc will pay these investors $0.05 per share each month from May 12, 2022 to August 12, 2022 if the deal has not closed by that time.

The parties initially announced their $449 million combination on February 2. La Jolla, California-Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that delivers oncolytic viruses for targeted therapy against difficult-to-treat cancers.

 

Recent Posts
by Kristi Marvin on 2025-03-15 at 10:02am

Terms Tracker for the Week Ending March 14, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Once again, market volatility was the headline news this week, and while that doesn’t directly affect SPACs, it has some effect. For investors, it’s usually...

by Nicholas Alan Clayton on 2025-03-14 at 8:17am

At the SPAC of Dawn The first wave of proposed SEC rules changes under the Trump administration touch upon SPACs in some unexpected ways and could portend at least a few years of peace between sponsors and their chief regulator. Earlier this month, the SEC announced that its Division of Corporation Finance would expand the...

by Nicholas Alan Clayton on 2025-03-13 at 8:17am

At the SPAC of Dawn Following Wednesday’s positive CPI readings, the market is set to ingest both new jobless claims and Core PPI inflation numbers at 8:30 am ET. It might take a particularly rosy result to offset the many factors of market volatility recent. One new one got added to the bingo card this...

by Nicholas Alan Clayton on 2025-03-12 at 3:48pm

One of the eternal questions surrounding SPACs has been their ability or inability to match the opportunity and the performance of the traditional IPO route, and it has become received wisdom on Wall Street that SPACs don’t match up. This is ostensibly born out in in the aggregate statistics that are frequently cited. But, downside...

by Nicholas Alan Clayton on 2025-03-12 at 8:17am

At the SPAC of Dawn Despite the specter of recession looming, many of the hot technology sectors that SPACs favored during the boom times appear to be coming back on the menu. Ares II (NYSE:AACT) is reportedly angling to lock down a deal with an autonomous trucking firm. Northern Genesis II and Reinvent Y each...

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved